A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

@article{Mooney2009API,
  title={A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.},
  author={Colin J Mooney and Govardhanan Nagaiah and Pingfu Fu and Jay K Wasman and Matthew M. Cooney and Panos S Savvides and Joseph A. Bokar and Afshin Dowlati and Ding Wang and Sanjiv S. Agarwala and Susan M Flick and Paul D. Hartman and Jos{\'e} David Canca Ortiz and Pierre N Lavertu and Scot C. Remick},
  journal={Thyroid : official journal of the American Thyroid Association},
  year={2009},
  volume={19 3},
  pages={233-40}
}
BACKGROUND Fosbretabulin is a novel vascular-disrupting agent that has antitumor activity against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a phase I trial. This phase II study determined the efficacy and safety of fosbretabulin in patients with advanced ATC and whether fosbretabulin altered the natural history of ATC by virtue of doubling the median survival. A secondary aim evaluated the prognostic value of serum soluble intracellular adhesion… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

A randomized phase 2 trial of combretatstatin A-4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies

  • WL Akerley, M Schabel, +4 authors K Arbogast
  • J Clin Oncol 2007 ASCO Ann Meeting Proc 25:616s…
  • 2007
3 Excerpts

Center Data Base report on 53 , 856 cases of thyroid carcinoma treated in the US , 1985 – 1995

  • A Jemal, R Siegel, E Ward, T Murray, J Xu, MJ Thun
  • 2007

Complications FOSBRETABULIN IN ANAPLASTIC THYROID CANCER 239 from vascular-disrupting agents and angiogenesis inhibi- tors: aberrant control of hemostasis and thrombosis

  • WJ van Heeckeren, SL Sanborn, +4 authors SC Remick
  • Curr Opin Hematol 14:468–480
  • 2007
1 Excerpt

Exaggerated hyper- tensive response of combretastatin A-4 phosphate in hyper- tensive rats

  • Q Ke, N Bodyak, D Rigor, P Kang
  • International Conference of Vascular Targeted…
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…